Results 141 to 150 of about 23,180 (193)

Study of Management of Mucormycosis in COVID and Post-COVID Patients with Liposomal Amphotericin B its Outcome and Complications in a dedicated COVID Hospital from Eastern India. [PDF]

Niger Med J
Dinkar JK, Ranjan R, Priyanka, Kumar S, Kumar N.   +4 more
europepmc   +1 more source

Treatment Outcomes of Single-Dose Liposomal Amphotericin B-Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India. [PDF]

Am J Trop Med Hyg
Siddiqui NA, Ansari MZ, Sinha SK, Pal B, Singh AK, Singh SK, Topno RK, Rabi Das VN, Pandey K.   +8 more
europepmc   +1 more source

Cutaneous Mucormycosis of the Eyelid Treated With Subcutaneous Liposomal Amphotericin B Injections. [PDF]

Ophthalmic Plast Reconstr Surg
Smith LD, Ahmad M, Ashraf DC, Kersten RC, Winn BJ, Grob SR, Vagefi MR.   +6 more
europepmc   +1 more source

A fatal case of disseminated microsporidiosis due to Anncaliia algerae in a renal and pancreas allograft recipient [PDF]

, 2019
Anderson, Neil W, Arif, Sana, Bruminhent, Jackrapong, Deziel, Paul J, Metcalfe, Maureen G, Muehlenbachs, Atis, Pritt, Bobbi S, Qvarnstrom, Yvonne, Razonable, Raymund R, Wilhelm, Mark P   +9 more
core   +1 more source

Cerebral aspergillosis in a patient with leprosy and diabetes: a case report [PDF]

, 2014

core   +1 more source

Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study. [PDF]

Clin Infect Dis
Gakuru J, Kagimu E, Dai B, Okurut S, Nsangi L, Bahr NC, Okirwoth M, Namuju OC, Jarvis JN, Lawrence DS, Ahimbisibwe C, Ellis J, Tadeo KK, Boulware DR, Meya DB, Tugume L.   +15 more
europepmc   +1 more source

Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review. [PDF]

J Antimicrob Chemother
Lai T, Yeo CY, Rockliff B, Stokes M, Kim HY, Marais BJ, McLachlan AJ, Alffenaar JC.   +7 more
europepmc   +1 more source

Paving the way for affordable and equitable liposomal amphotericin B access worldwide.

Lancet Glob Health
Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC, Chung HY, Costa LH, Ford N, Galvao DLN, Giron N, Jarvis JN, Mondal M, Odionyi JJ, Casas CP, Rangaraj A, Rode J, Ruffell C, Sued O, Ribeiro I.   +18 more
europepmc   +1 more source

Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. [PDF]

Antimicrob Agents Chemother
Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS.   +8 more
europepmc   +1 more source

Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Candida species in an in vitro pharmacokinetic/pharmacodynamic model. [PDF]

Antimicrob Agents Chemother
Beredaki M-I, Arendrup MC, Pournaras S, Meletiadis J.   +3 more
europepmc   +1 more source